Thieno[3,2-b]pyridin-7-amine Compounds for Treating Familial Dysautonomia

The EPO published patent EP3924049A1 for PTC Therapeutics covering thieno[3,2-b]pyridin-7-amine compounds classified under A61K 31/4365 for treating familial dysautonomia, a rare genetic disorder affecting the autonomic nervous system. The patent names nine inventors and designates 38 European contracting states including AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, and TR.

For pharmaceutical manufacturers and biotech companies developing rare disease therapies, this patent establishes PTC Therapeutics' intellectual property position in the EU for this specific compound class. Competitors pursuing similar mechanisms for familial dysautonomia must evaluate potential infringement risks and consider patent clearance strategies or licensing negotiations before market entry in designated European territories.